ArticleHealth science reports2025
Determinants of Antibody Reactivity in COVID-19: A Case-Control Study in a Middle Eastern Cohort.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Understanding the determinants of humoral immunity following COVID-19 infection is essential for guiding vaccination and public health strategies. This study aimed to investigate the association between cycle threshold (Ct) values and SARS-CoV-2-specific antibody reactivity 1 month after recovery in a Middle Eastern cohort, and to identify other contributing factors. Methods: A case-control study was conducted among COVID-19 patients registered in the Qatar Biobank between March and September 2020. Cases were defined as individuals with detectable anti-SARS-CoV-2 antibodies 1-month post-recovery, while controls lacked antibody reactivity. Demographics, comorbidities, Ct values, and disease severity were collected at baseline. Logistic regression was used to analyze factors associated with antibody reactivity, with results adjusted for key covariates. Results: Among 225 participants, 177 (78.7%) exhibited reactive anti-SARS-CoV-2 IgG antibodies 1-month post-recovery. Among participants with reactive antibodies, 74.0% were from severe and critical cases. Lower Ct values (< 20), indicating higher viral load, were associated with increased odds of antibody reactivity (OR 2.03, 95% CI 0.97-4.24, Conclusion: Ct values and male gender may serve as significant predictors of antibody-mediated immunity to COVID-19 infection. Larger studies are needed to validate these findings, identify vulnerable individuals who may benefit from booster vaccination, and explore their relevance to other respiratory pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.